Randomization and Baseline Data
nausea
Patients were entered on this clinical trial from 111 clinical sites between October 2018 and July 2021. Each participant signed an IRB-approved, protocol-specific informed consent document in accordance with federal and institutional guidelines. Data regarding the distribution and randomization of the 690 entered patients are illustrated in a CONSORT diagram (Baseline characteristics.
CONSORT diagram.There were no differences between the 2 study arms with regard to the patients’ symptoms over the 24 hours prior to receipt of their chemotherapy as it related to their (1) worst nausea scores, (2) an undesired increase in their appetite, or (3) undesired sedation.